Dec. 14 at 1:19 AM
$UNCY
As of late 2025, Unicycive Therapeutics (
$UNCY) Direct common shares ~2,530,000 Shares owned outright by the CEO +
Stock options / derivatives ~968,951 Options that can convert to shares if exercised.
Total holding by ceo is approx 3,500,000 shares post reverse split adjusted ( with options fully exercised).
That represents -16% of total shares outstanding (21,490,000 shares).
Institution Shares Held % Ownership Type of Investor
Vivo Capital, LLC ~1.79 Million ~8.3% Healthcare VC/Private Equity
Octagon Capital Advisors ~1.00 Million ~4.7% Life Sciences Hedge Fund
Nantahala Capital Mgmt ~940,000 ~4.4% Small-Cap Focused Fund
Great Point Partners ~800,000 ~3.7% Healthcare Investment Firm
The Vanguard Group ~660,000 ~3.1%.
Vivo Capital is currently the largest institutional holder. In the most recent reporting period (Q3 2025), they reportedly increased their position by over 50%.
Avg price tgt by 5 analysts 💲46.5
Its a patience play.
GLTA.
